Documenting the compounding and telehealth economy in real time.
Apr 13, 2026
•
6 min read
Vol. XIV Retatrutide Will Change Everything. But We're Not There Yet.
Apr 6, 2026
Vol. XIII Peptides Are Coming Back. Is Your Practice Ready?
Mar 30, 2026
7 min read
Vol. XII Your Name Is on the Door. Act Like It.
Mar 23, 2026
Vol. XI Your Lab Rat Era Is Over
Mar 16, 2026
Vol. X Novo drops lawsuit against Hims & Hers - GLP-1s Were Not the Breakthrough. It Was the Proof of Scale.
Mar 9, 2026
11 min read
Vol. IX The Signal Nobody Wanted to Hear (But Everybody Needed) + So You've Been Playing in the Gray Market. Now What?
Mar 2, 2026
Vol. VIII My follow up take on RFK's big news drop on Rogan + What you should do as a Clinic right now
Feb 23, 2026
Vol. VII What a Compliant Peptide Program Actually Looks Like +How to Evaluate a Compounding Pharmacy Before You Need To
Feb 16, 2026
Vol. VI Research Peptides & Brand Risk + The FDA Letter directed at HIMs and the bugs and rodents that inspired it.
Feb 9, 2026
Vol. V GLP-1s and the role of AI in Cancer Screening From Metabolic Therapy to Predictive Oncology
Jan 28, 2026
Vol. IV Pep Talk and How to Fit Them into Your Practice
Jan 13, 2026
Vol. III Infrastructure and Retention
Jan 4, 2026
8 min read
Vol. II Outside the System & Peptide Deep Dive
Dec 30, 2025
Vol. I Modern therapies don’t succeed because they’re innovative, they succeed when the systems around them hold.
